OpenLegislation

Paragraph 3 Marketing authorizations

Changes not yet applied. Later legislation changes this provision in ways not yet written into the text below:

Subject to paragraph 4, where a marketing authorization is held in respect of a derivative of a new active substance, the fee payable under regulation 14(3) shall be—

(a)

where it is of the same dosage form as, but of a different strength of active ingredient or different combination of active ingredients from, that relating to the new active substance, £3,575;

(b)

where it is of a different dosage form from that relating to the new active substance, £5,950.